Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines

Holzhauser,Stefan; Lukoseviciute,Monika; Papachristofi,Christina; Vasilopoulou,Christina; Herold,Nikolas; Wickström,Malin; Kostopoulou,Ourania  N.; Dalianis,Tina

doi:10.3892/ijo.2021.5167

Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines

Authors:
- Stefan Holzhauser
- Monika Lukoseviciute
- Christina Papachristofi
- Christina Vasilopoulou
- Nikolas Herold
- Malin Wickström
- Ourania N. Kostopoulou
- Tina Dalianis
View Affiliations

Affiliations: Department of Oncology‑Pathology, Karolinska Institutet, 17164 Stockholm, Sweden, Children and Women's Health, Karolinska Institutet, 17164 Stockholm, Sweden
Published online on: January 5, 2021 https://doi.org/10.3892/ijo.2021.5167
Pages: 211-225
Copyright: © Holzhauser et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuroblastoma (NB) is a heterogenous disease with treatment varying from observation for low‑risk tumors, to extensive therapy with chemotherapy, surgery, radiotherapy, and autologous bone‑marrow‑transplantation and immunotherapy. However, a high frequency of primary‑chemo‑refractory disease and recurrences urgently require novel treatment strategies. The present study therefore investigated the anti‑NB efficacy of the recently FDA‑approved phosphoinositide 3‑kinase (PI3K) and fibroblast growth factor receptor (FGFR) inhibitors, alpelisib (BYL719) and erdafitinib (JNJ‑42756493), alone and in combination with or without cisplatin, vincristine, or doxorubicin on 5 NB cell lines. For this purpose, the NB cell lines, SK‑N‑AS, SK‑N‑BE(2)‑C, SK‑N‑DZ, SK‑N‑FI and SK‑N‑SH (where SK‑N‑DZ had a deletion of PIK3C2G and none had FGFR mutations according to the Cancer Program's Dependency Map, although some were chemoresistant), were tested for their sensitivity to FDA‑approved inhibitors alone or in combination, or together with cytostatic drugs by viability, cytotoxicity, apoptosis and proliferation assays. The results revealed that monotherapy with alpelisib or erdafitinib resulted in a dose‑dependent inhibition of cell viability and proliferation. Notably, the combined use of PI3K and FGFR inhibitors resulted in an enhanced efficacy, while their combined use with the canonical cytotoxic agents, cisplatin, vincristine and doxorubicin, resulted in variable synergistic, additive and antagonistic effects. Collectively, the present study provides pre‑clinical evidence that PI3K and FGFR inhibitors exhibit promising anti‑NB activity. The data presented herein also indicate that the incorporation of these inhibitors into chemotherapeutic regimens requires careful consideration and further research in order to obtain a beneficial efficacy. Nevertheless, the addition of PI3K and FGFR inhibitors to the treatment arsenal might reduce the occurrence of refractory and relapsing disease in NB without FGFR and PI3K mutations.

View Figures

View References

1	Ward E, DeSantis C, Robbins A, Kohler B and Jemal A: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 64:83–103. 2014. View Article : Google Scholar : PubMed/NCBI
2	Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK and Hogarty M: COG Neuroblastoma Committee. Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatr Blood Cancer. 60:985–993. 2013. View Article : Google Scholar
3	London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A and Park JR: Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. Cancer. 123:4914–4923. 2017. View Article : Google Scholar : PubMed/NCBI
4	AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov. 7:818–831. 2017. View Article : Google Scholar : PubMed/NCBI
5	Trigg RM and Turner SD: ALK in neuroblastoma: Biological and therapeutic implications. Cancers (Basel). 10:1132018. View Article : Google Scholar
6	Guan J, Fransson S, Siaw JT, Treis D, Van den Eynden J, Chand D, Umapathy G, Ruuth K, Svenberg P, Wessman S, et al: Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib. Cold Spring Harb Mol Case Stud. 4:a0025502018. View Article : Google Scholar : PubMed/NCBI
7	Wesche J, Haglund K and Haugsten EM: Fibroblast growth factors and their receptors in cancer. Biochem J. 437:199–213. 2011. View Article : Google Scholar : PubMed/NCBI
8	Parker BC, Engels M, Annala M and Zhang W: Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours. J Pathol. 232:4–15. 2014. View Article : Google Scholar : PubMed/NCBI
9	Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, et al: Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget. 7:57525–57544. 2016. View Article : Google Scholar : PubMed/NCBI
10	Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D and Weiss WA: Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66:8139–8146. 2006. View Article : Google Scholar : PubMed/NCBI
11	Segerström L, Baryawno N, Sveinbjörnsson B, Wickström M, Elfman L, Kogner P and Johnsen JI: Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer. 129:2958–2965. 2011. View Article : Google Scholar : PubMed/NCBI
12	Klempner SJ, Myers AP and Cantley LC: What a tangled web we weave: Emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov. 3:1345–1354. 2013. View Article : Google Scholar : PubMed/NCBI
13	Yang J, Nie J, Ma X, Wei Y, Peng Y and Wei X: Targeting PI3K in cancer: Mechanisms and advances in clinical trials. Mol Cancer. 18:262019. View Article : Google Scholar : PubMed/NCBI
14	Kostopoulou ON, Holzhauser S, Lange BKA, Ohmayer A, Andonova T, Bersani C, Wickström M and Dalianis T: Studies of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors in neuroblastoma cell lines. Int J Oncol. 55:1372–1384. 2019.PubMed/NCBI
15	Biedler JL, Helson L and Spengler BA: Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 33:2643–2652. 1973.PubMed/NCBI
16	Biedler JL and Spengler BA: A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chines hamster cell lives in culture. J Natl Cancer Inst. 57:683–695. 1976. View Article : Google Scholar : PubMed/NCBI
17	Sugimoto T, Tatsumi E, Kemshead JT, Helson L, Green AA and Minowada J: Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer Inst. 73:51–57. 1984.PubMed/NCBI
18	Helson L and Helson C: Human neuroblastoma cells and 13-cis-retinoic acid. Neurooncol. 3:39–41. 1985.
19	LaQuaglia MP, Kopp EB, Spengler BA, Meyers MB and Biedler JL: Multidrug resistance in human neuroblastoma cells. J Pediatr Surg. 26:1107–1112. 1991. View Article : Google Scholar : PubMed/NCBI
20	Holzhauser S, Lukoseviciute M, Andonova T, Ursu RG, Dalianis T, Wickström M and Kostopoulou ON: Targeting fibroblast growth factor receptor (FGFR) and phosphoinositide 3-kinase (PI3K) signaling pathways in medulloblastoma cell lines. Anticancer Res. 40:53–66. 2020. View Article : Google Scholar : PubMed/NCBI
21	André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, et al: Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 380:1929–1940. 2019. View Article : Google Scholar
22	Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, Awad M, Calvo E, Moreno V, Govindan R, et al: Multicenter phase I study of erdafitinib (JNJ-42756493), Oral Pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 25:4888–4897. 2019. View Article : Google Scholar : PubMed/NCBI
23	Foucquier J and Guedj M: Analysis of drug combinations: Current methodological landscape. Pharmacol Res Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
24	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
25	Holzhauser S, Kostopoulou ON, Ohmayer A, Lange BKA, Ramqvist T, Andonova T, Bersani C, Wickström M and Dalianis T: In vitro antitumor effects of FGFR and PI3K inhibi-tors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines. Oncol Lett. 18:6249–6260. 2019.PubMed/NCBI
26	Wang L, Šuštić T, Leite de Oliveira R, Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den Heuvel MM, Bernards R and van der Heijden MS: A functional genetic screen identifies the phosphinositide 3-kinase pathway as a determinant of resistance to fibroblast grown factor receptor inhibitors in FGFR mutant urothelial cell carcinoma. Eur Urol. 71:858–862. 2017. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Mikse O, Liao RG, Li Y, Tan L, Janne PA, Gray NS, Wong KK and Hammerman PS: Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 34:2167–2177. 2015. View Article : Google Scholar
28	Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A and Turner NC: Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov. 3:1058–1071. 2013. View Article : Google Scholar : PubMed/NCBI
29	Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter UDA: Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Oncol Rep. 38:1877–1885. 2017. View Article : Google Scholar : PubMed/NCBI
30	Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC and Heasley LE: Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 pathways for treatment of lung cancer and HNSCC. Cancer Res. 75:4398–4406. 2015. View Article : Google Scholar : PubMed/NCBI
31	Cai W, Song B and Ai H: Combined inhibition of FGFR and mTOR pathways is effective in suppressing ovarian cancer. Am J Transl Res. 11:1616–1625. 2019.PubMed/NCBI
32	Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, et al: First-in-Human phase I study of GSK2126458, an Oral Pan-class I Phosphatidylinositol-3-Kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res. 22:1932–1939. 2016. View Article : Google Scholar
33	Tamura R, Yoshihara K, Saito T, Ish imura R, Martínez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda K, et al: Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions. Oncogenesis. 7:42018. View Article : Google Scholar : PubMed/NCBI
34	Fulda S, Honer M, Menke-Moellers I and Berthold F: Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Eur J Cancer. 31A:616–621. 1995. View Article : Google Scholar : PubMed/NCBI
35	Zheng X, Naiditch J, Czurylo M, Jie C, Lautz T, Clark S, Jafari N, Qiu Y, Chu F and Madonna MB: Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics. Cell Death Dis. 4:e7402013. View Article : Google Scholar : PubMed/NCBI
36	Eschenburg G, Luckert C, Reinshagen K and Bergholz R: Taurolidine cooperates with antineoplastic drugs in neuroblastoma cells. Genes Cancer. 5:460–469. 2014. View Article : Google Scholar
37	Wickström M, Johnsen JI, Ponthan F, Segerström L, Sveinbjörnsson B, Lindskog M, Lövborg H, Viktorsson K, Lewensohn R, Kogner P, et al: The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo. Mol Cancer Ther. 6:2409–2417. 2007. View Article : Google Scholar : PubMed/NCBI
38	Wong CH, Ma BB, Cheong HT, Hui CW, Hui EP and Chan AT: Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC). Am J Cancer Res. 5:1496–1506. 2015.PubMed/NCBI
39	Keam B, Kim S, Ahn YO, Kim TM, Lee SH, Kim DW and Heo DS: In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 35:175–182. 2015.PubMed/NCBI
40	Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, et al: Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: A dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 20:570–580. 2019. View Article : Google Scholar : PubMed/NCBI